WO1997008205B1 - Antibodies having two or more specificities for the selective elimination of cells in vivo - Google Patents

Abstract

The invention concerns antibodies having two or more specificities detecting two different antigens localized on a tumour cell. The invention further concerns medicaments and diagnostic compositions containing these antibodies. The antibodies and medicaments described are suitable in particular for specifically detecting and eliminating tumour cells in vivo or in vitro.

Claims

AMENDED CLAIMS [received at the International Bureau on 14 April 1997 (14.04.97); original claims 1-20 replaced by amended claims 1-16 (3 pages)] 1. Antibody having at least three specificities, characterized ge indicates that are recognized by at least two antigen binding sites of the antibody with different specificity two different located on a tumor cell antigens and another antigen binding site with a further specificity an isolated on an effector cell antigen recognizes. 2. Antibody according to claim 1, characterized in that two different tumor-associated antigens wer¬ recognized by the antigen binding sites that recognize two unterschiedli¬ che located on the tumor cell antigens. 3. Antibody according to claim 1, characterized in that of the antigen binding sites which recognize two unterschiedli¬ che on the tumor cell localized antigens, at least one antigen binding site recognizes a tumorassozi¬ iert antigen and at least one further anti¬ gene binding site recognizes an antigen that also from non-malignant cells is expressed. 4. The antibody of claim 3, wherein the antigen also expressed by non-malignant cells is an antigen specific to the cell or tissue type of the tumor. 5. An antibody according to claim 1, characterized in that two non-tumor-specific antigens are detected by the antigen binding sites that recognize two unterschiedli¬ che on a tumor cell located antigens that occur in combination exclusively or almost exclusively on the tumor cell. 6. An antibody according to any one of claims 1 to 5, wherein the tumor cell located on the antigens antigens CD1, CD2, CD4, CD6, CD7, CD8, CD10, CDU, CD13, CD14, CD23, CD24, an Ig idiotype, CD30 , CD33, CD37, CD40, CD41, c-erb-B2, CALLA (CD10), MHCII, CD44v3, CD44v6, CD71, p97, ganglioside G _D _ _2, GD3, C215, that of the monoethylenically clonal antibody 17- IA-recognized antigen, the antigen recognized by the monoclonal antibody 9.2.27, the antigen recognized by the monoclonal antibody NE150, the antigen recognized by the monoclonal antibody L6, the antigen recognized by the monoclonal antibody CA125 (Mucin), the antigen is Lewis y, CD19, CD20, CD21, CD22, B220 or CD5. 7. Antibody according to one of claims 1 to 6, characterized ge indicates that the localized on the effector cell antigen is not present on the tumor cell. 8. Antibody according to one of claims 1 to 7, characterized ge indicates that it is the antigen located on the effector cell to the antigen CD3, CD16, CD28, CD32 or CD64. 9. An antibody according to any one of claims 1 to 8, wherein it is a monoclonal antibody, an antibody produced by re¬ combinant DNA technology, a semisynthetic or synthetic antibody, a chemically modified antibody or a fragment of such an antibody. 10. An antibody according to any one of claims 1 to 9, wherein the antibody is coupled with an enzyme, a toxi¬'s substance, a radionuclide, biotin or a superantigen. 11. A medicament containing at least one antibody according to any one of claims 1 to 10. 12. Use of an antibody according to any one of claims 1 to 10 for the manufacture of a medicament for in vivo immunotherapy. 13. Use according to claim 12, wherein the immunotherapy is a therapy for the treatment of a tumor. 14. Use according to claim 13, wherein the tumor is a leukemia, a colorectal carcinoma, a melanoma, an ovarian carcinoma, a glioblastoma (malignant glioma) or a mammary carcinoma. Use according to claim 14, wherein the leukemia is a B-cell lymphoma or a T-cell lymphoma. 16. A diagnostic composition comprising at least one antibody according to any one of claims 1 to 10.